Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.